S
Sandeep Tyagi
Researcher at Johns Hopkins University School of Medicine
Publications - 23
Citations - 2508
Sandeep Tyagi is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Mycobacterium tuberculosis & Tuberculosis. The author has an hindex of 19, co-authored 23 publications receiving 2220 citations.
Papers
More filters
Journal ArticleDOI
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Vadim Makarov,Giulia Manina,Katarína Mikušová,Ute Möllmann,O. B. Ryabova,Brigitte Saint-Joanis,Neeraj Dhar,Maria Rosalia Pasca,Silvia Buroni,Anna Paola Lucarelli,Anna Milano,Edda De Rossi,Martina Belanova,Adela Bobovská,Petronela Dianišková,Jana Korduláková,Claudia Sala,Elizabeth Fullam,Patricia Schneider,John D. McKinney,Priscille Brodin,Thierry Christophe,Simon J. Waddell,Philip D. Butcher,Jakob Albrethsen,Ida Rosenkrands,Roland Brosch,Vrinda Nandi,Sowmya Bharath,Sheshagiri Gaonkar,Radha Shandil,V. Balasubramanian,Tanjore S. Balganesh,Sandeep Tyagi,Jacques H. Grosset,Giovanna Riccardi,Stewart T. Cole +36 more
TL;DR: The synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB are described.
Journal ArticleDOI
Targeting DnaN for tuberculosis therapy using novel griselimycins
Angela Kling,Peer Lukat,Deepak V. Almeida,Armin Bauer,Evelyne Fontaine,Sylvie Sordello,Nestor Zaburannyi,Jennifer Herrmann,Silke C. Wenzel,Claudia König,Nicole C. Ammerman,María Belén Barrio,Kai Borchers,Florence Bordon-Pallier,Mark Brönstrup,Courtemanche Gilles,Martin Gerlitz,Michel Geslin,Peter Hammann,Dirk W. Heinz,Holger Hoffmann,Sylvie Klieber,Markus Kohlmann,Michael Kurz,Christine Lair,Hans Matter,Eric L. Nuermberger,Sandeep Tyagi,Laurent Fraisse,Jacques H. Grosset,Sophie Lagrange,Rolf Müller +31 more
TL;DR: It is shown that new optimized derivatives from Streptomyces-derived griselimycin are highly active against M. tuberculosis, both in vitro and in vivo, by inhibiting the DNA polymerase sliding clamp DnaN.
Journal ArticleDOI
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Ian M. Rosenthal,Ming Zhang,Kathy N. Williams,Charles A. Peloquin,Sandeep Tyagi,Andrew Vernon,William R. Bishai,William R. Bishai,Richard E. Chaisson,Richard E. Chaisson,Jacques H. Grosset,Eric L. Nuermberger,Eric L. Nuermberger +12 more
TL;DR: It is demonstrated that replacing rifampin with rifapentine and isoniazid with moxifloxacin dramatically increased the activity of the standard daily regimen, which may permit shortening the current 6 mo duration of treatment to 3 mo or less.
Journal ArticleDOI
Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model
Kathy N. Williams,Charles K. Stover,Tong Zhu,Rokeya Tasneen,Sandeep Tyagi,Jacques H. Grosset,Eric L. Nuermberger +6 more
TL;DR: It is suggested that PNU-100480 may have the potential to significantly shorten the duration of therapy for drug-susceptible as well as multidrug-resistant tuberculosis.
Journal ArticleDOI
Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs.
TL;DR: Thirty-one M. tuberculosis genes were found to be required for in vivo survival in mouse lungs, and most of the genes are conserved in other pathogenic mycobacteria, including M. leprae and M. bovis, suggesting that a core of basic in vitro survival mechanisms may be highly conserved despite the divergent human pathology caused by members of the myc Cobacterial genus.